The COVID-19 pandemic initiated a huge pharmaceutical effort to tackle the virus at the cause, resulting in a surge in innovation in vaccines and antiviral drugs. This is an R&D trend that is likely to continue in an attempt to protect ourselves from future outbreaks. In this article, IP Analyst Akshay Thaman discusses antiviral tech in the UK, the demographic of patented technologies in this field and how far away we are from being proactive rather than reactive to crises.
WHEN COVID-19 reared its head at the end of 2019, it was not without warning. Despite various scientific papers, activists and special interest groups warning of a potential pandemic for some time, the world found itself ill-prepared for what was to come. As countries, including the UK, scrambled to secure personal protective equipment (PPE) for their health workers and adequate testing capacity for their citizens, the historic underinvestment in the development of antiviral drugs became increasingly apparent.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
What followed was an unprecedented global effort to overcome the social, economic and health impact of SARS-CoV-2, the virus that causes COVID-19. As the virus brought daily life to a screeching halt in country after country, governments, organisations and companies joined forces to respond to the crisis on a scale that has never been seen before.
Analysing patent data to spot trends and identify exploitable gaps in the market is key to this paradigm shift”
Shortly after the start of the pandemic, the University of Oxford’s RECOVERY trial found the well-known, inexpensive steroid dexamethasone was able to reduce deaths in ventilated patients by a third and in those needing oxygen by a fifth, and pharma and biotech companies the world over were working on possible COVID-19 treatments. Of course, such successes are to be celebrated, but amid repeated warnings that this pandemic will not be our last, it could be argued that we need a proactive – rather than a reactive – approach to treating such disruptive diseases.
Analysing patent data to spot trends and identify exploitable gaps in the market is key to this paradigm shift. Organisations can use this information to construct an innovation landscape to both inform their own R&D strategies and to predict those of their competitors. Crucially, patent data analyses can deliver the information companies need to be proactive.
Antiviral tech in the UK
UK patent data from the antiviral space (Figure 1) shows spikes in filings in 2002, 2006, 2009, 2015 and 2017 – all of which are years that correlate with the emergence of various viral diseases, such as the SARS (Severe Acute Respiratory Syndrome) and MERS (Middle Eastern Respiratory Syndrome) outbreaks in 2012 and 2015, H5N1 in 2006, and H1N1 in 2009. While this trend has declined over time, it is highly likely that 2020 data will show a record number of filings thanks to the COVID-19 pandemic. This information is suggestive of an industry reacting to, rather than preparing for, viral crises. Some industry players are waking up to this opportunity and it is interesting to see how the patent landscape can provide a window into differing strategies.
Figure 1: Number of patent filings per filing year for patents within the antiviral space in the UK
Data show that GSK and Oxford Innovation have, for example, been filing high volumes of patents in a bid to secure their freedom to operate in the antiviral space. This points to a continuous R&D pipeline and a desire to maintain market leader status by developing industry-leading tech on a regular basis. Others, such as 4D Pharma, AbbVie and Immunocore, appear to have adopted more of an ‘opportunistic’ approach, filing high-quality patents when the opportunity arises through existing R&D projects.
How the UK compares
Global trends show that investment in patent activity has increased over time. This is in contrast to the overall pattern in the UK, where filings have been decreasing outside of the outbreak-related spikes outlined above. The USA is the most active in the space, possibly because of steady governmental support. In fact, data from PatentSight show the US Government has filed or acquired 274 patent families since 2000, second only to GSK, which recorded 302 patent families.
The overall worldwide increase in patents could well be attributable to countries responding to local epidemics – which is further evidence of the reactive nature of antiviral R&D. The uplift in filings from China between 2003 to 2008, for instance, is likely to have been a result of the 2002 SARS outbreak and South Korea’s patent growth between 2015 and 2018 may have been a direct response to the emergence of MERS in May 2015. Incidentally, some may argue that this experience may have been instrumental in South Korea’s lauded tackling of COVID-19.
Time for a proactive approach
Patent data analysis confirms that antiviral research follows a reactive, rather than proactive, path. While we are yet to see the data from 2020, it is almost certain that they will show an increase in global filings and that this trend will continue until an effective vaccine is developed and enters the market.
The question remains whether the huge economic and social fallout caused by COVID-19 will act as the wake-up call for policy makers and investors to break the cycle of reactivity and inject the money needed to prepare the world for the next biological threat to our way of life.
About the author
Akshay Thaman works as an IP Analyst for GovGrant. He has a master’s degree in both Chemistry and Intellectual Property Law and gained commercial IP experience as an intern with a leading oil and gas company before joining GovGrant in 2020. Akshay helps UK businesses become the centre of innovation and works closely with GovGrant’s clients to uncover IP that may be hidden within their businesses.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.